Deep Functional Phenotyping of the ALA Lung Health Cohort
NCT06177717
Lung Diseases, Respiratory Tract Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT Number: NCT04543461
The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.
Interested in participating?
Request Info25 year–35 year
All sexes
Observational
University Of Alabama, Birmingham, Alabama, United States
The scientific goal of the study is to establish the relationship between a variety of factors (lifetime environmental exposures, fitness and physical activity, biomarkers, nasal respiratory epithelial transcriptome) and ideal versus impaired peak lung health (reserve and markers of susceptibility in investigators' model) in young adulthood. In addition to the initial baseline assessment, remote contacts (e.g., via text message, email, mail, or phone) at regular intervals will allow for both the retention of the participants as well as the collection of additional short-term follow-up information, i.e., within 4.5 years of enrollment. If additional funding becomes available, investigators will extend the study for an additional period of time to study factors related to long-term changes in lung health over time, i.e., at 5 years and beyond. Recruitment of participants will be conducted by the participating study sites along with national and regional efforts from the American Lung Association. Recruitment efforts will be supported by the study web site www.lung.org/lung-study
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
1- Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.
5- Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant
Exclusion criteria
OR
Time frame: Baseline
Pre-bronchodilator measurements of FEV1 to determine bronchoconstriction. FEV1 is measured in liters of air. Severity of bronchoconstriction is based on predicted values published by National Health and Nutrition Examination Survey (NHANES III hankinson) for height, weight and age. Predicted values are reported as percent predicted with a result of 80% or greater considered normal
Time frame: Baseline
Pre-bronchodilator measurements FVC to determine lung volume. FVC is measured in liters of air. Participants predicted vital lung capacity is based on values published by National Health and Nutrition Examination Survey (NHANES III hankinson) for height, weight and age. Predicted values are reported as percent predicted with a result of 80% or greater considered normal
Contact information is provided by the study sponsor or research team.
Curt Reynolds, MAS
CONTACT
Elizabeth Sugar, PhD
CONTACT
Johns Hopkins University
Other
The American Lung Association (ALA) Lung Health Cohort
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06177717
Lung Diseases, Respiratory Tract Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06925373
Chronic Disease, Disease Attributes
Birmingham, Alabama, United States
View Trial DetailsNCT05922761
Bronchial Diseases, Bronchiolitis
Stanford, California, United States
View Trial DetailsNCT07227376
Lung Diseases, Pathological Conditions, Signs and Symptoms
Jacksonville, Florida, United States
View Trial Details